Vasa-european Journal of Vascular Medicine最新文献

{"title":"Patient participation in supervised exercise therapy and its impact on outcomes and quality of life in peripheral arterial disease.","authors":"Waseem Garabet, Katharina Henrika Beckamp, Polina Shabes, Markus Udo Wagenhäuser, Amir Arnautovic, Artis Knapsis, Philip Dueppers, Nadja Kairies-Schwarz, Hubert Schelzig, Julian-Dario Rembe","doi":"10.1024/0301-1526/a001280","DOIUrl":"https://doi.org/10.1024/0301-1526/a001280","url":null,"abstract":"<p><p><b></b> <i>Background:</i> Supervised Exercise Therapy (SET) improves walking performance in patients with peripheral arterial disease (PAD) and intermittent claudication, yet implementation and adherence remain inconsistent. This study evaluated functional outcomes, ankle-brachial index (ABI), quality of life (QoL), and adherence to SET in a real-world clinical setting. <i>Materials and methods:</i> This monocentric retrospective cohort study included 190 patients with PAD Fontaine stage II treated at a university vascular outpatient clinic between 01.01.2018 and 31.12.2022. Exposure was participation in SET compared with standard care without SET. Claudication onset distance (COD), peak walking distance (PWD), and ABI were assessed at baseline and after 3, 6, 12, and 24 months. Health-related QoL was evaluated using the SF-36 questionnaire. Adherence and reasons for dropout or non-participation were extracted from medical records. <i>Results:</i> Of the 190 patients (mean age 71.4 years; 60.5% male), 32 (16.8%) completed 12 months of SET, while 158 (83.2%) served as the comparison group. SET participants were older and predominantly male. COD and PWD improved significantly after 6 months (p = .0001 and p = .041) and continued to rise through 24 months, whereas ABI showed no significant changes. Adherence to SET was low. Dropout was mainly related to clinical deterioration, comorbidities, or hospitalisation, with additional sociodemographic and motivational barriers contributing to non-participation. SF-36 scores did not differ significantly, although trends toward reduced pain and improved physical functioning were observed. <i>Conclusions:</i> In this single-centre cohort, SET was associated with improved walking performance but low adherence and no significant changes in ABI or overall QoL.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of the effect of saphenous reflux treatment by prior ultrasound probe occlusion.","authors":"Erika Mendoza, Christopher R Lattimer","doi":"10.1024/0301-1526/a001272","DOIUrl":"https://doi.org/10.1024/0301-1526/a001272","url":null,"abstract":"<p><p><b></b> <i>Background:</i> This proof-of-concept study aims to determine whether the haemodynamic effect of saphenous treatment can be predicted using the saphenous occlusion test (SOT). <i>Materials and methods:</i> Fifteen legs (11 patients) with chronic venous disease and 12 legs of healthy controls were assessed using air plethysmography (APG) on a manually operated tilt table transitioning from near-standing to a -40° head-down position and back to control leg filling via APG. Measurements were taken: (i) preoperatively, (ii) during ultrasound-guided compression of the saphenous vein at the thigh (SOT), and (iii) after treatment of the GSV with proximal short-segment endovenous laser ablation (EVLA, not the controls). Clinical CEAP classification: C2 = 2, C3 = 4, C4a = 10, and C6 = 1, median Venous Clinical Severity Score (VCSS) of 5 [2-14]. Median follow 73 [30-89] days. <i>Results:</i> Both, the venous filling index (VFI, mL/s) and venous filling time (VFT90, in seconds) improved significantly with GSV probe compression and EVLA (p < .0005): VFI from baseline 2.6[2-3.3] and predicted 1.2 [1.1-1.6] to postoperative 1.3 [1.1-1.7], VFT90 from baseline 34.7 [23.8-40.1] and predicted 71.4 [46-89.9] to 70.7 [47.9-76]. No significant difference was found between the predicted and actual post-treatment values for VFI (p = .601) or VFT90 (p = 1). Significant difference between controls and patients (VFT90 p < .01, VFI p < .001) was lost after treatment (VFT90 p = .751, VFI p = .826). <i>Conclusions:</i> The haemodynamic effect of saphenous reflux correction can be accurately predicted using the saphenous occlusion test with APG together with orthostatic manoeuvres. This method may serve as a standardised, objective tool to evaluate the need for GSV intervention in patients with visible varicose veins.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volume reduction in leg lymphedema after comprehensive inpatient rehabilitation.","authors":"Felix Angst, Thomas Benz, Susanne Lehmann, Peter S Sándor, Stephan Wagner","doi":"10.1024/0301-1526/a001268","DOIUrl":"https://doi.org/10.1024/0301-1526/a001268","url":null,"abstract":"<p><p><b></b> <i>Background:</i> Data on volume changes after complex decongestive therapy (CDT) for leg lymphedema are sparse. This naturalistic prospective cohort study aimed to quantify the intraindividual changes of leg volume after comprehensive inpatient rehabilitation, focusing on intensive CDT, and to relate these changes to health-related quality of life (HRQOL). <i>Patients and methods:</i> Limb volume of patients with leg lymphedema (n = 101; 75 women) were measured between entry and discharge (3 weeks later) by the 4 cm measurement method according to Kuhnke and the Perometer® method. Changes were also expressed as standardised response means (SRM). The change on the Freiburg Quality of Life Assessment for lymphatic disorders, short version (FLQA-lk) total score was predicted using multivariate linear regression analysis with volume data adjusted for various confounders. <i>Results:</i> The overall mean volume decrease on the 4 cm/Perometer® method for both legs combined was 1.94/1.31 l for all patients, corresponding to SRMs of 1.04/0.86. In the lymphedema-affected limbs, the decreases ranged between 1.03 and 1.40 l/0.77 and 0.99 l (SRMs 0.70-1.72/0.67-1.28). The total volume loss (4 cm) of both legs of all n = 101 patients correlated by 0.240 (bivariate, p = .010) and by 0.216 (multivariate, adjusted, p = .045). <i>Conclusions</i>: After multidisciplinary rehabilitation focusing on intensive CDT, moderate to large effects on reducing limb volume were observed. Volume reduction was positively associated with improvement in HRQOL.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147435964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spot-stent grafting revisited - mid-term results of the treatment of Stanford type B aortic dissection and intramural haematoma.","authors":"Matthias Niklas Hagedorn, Moritz Sebastian Bischoff, Denis Skrypnik, Andreas Sebastian Peters, Dittmar Böckler, Katrin Meisenbacher","doi":"10.1024/0301-1526/a001279","DOIUrl":"https://doi.org/10.1024/0301-1526/a001279","url":null,"abstract":"<p><p><b></b> <i>Background:</i> Spot-stent grafting (SSG) for acute/subacute Stanford type B aortic dissection (ADB) and intramural hematoma (IMHB) entails selective coverage of the primary tear in the distal thoracic aorta (zones 4 or 5), with the stent graft fully deployed within the dissected segment-an intentional use beyond the Instructions for Use (IFU) aimed at minimising aortic coverage and preserving spinal cord perfusion. While early outcomes were favourable, long-term data on durability and reintervention remain limited. <i>Materials and methods:</i> In a single-centre retrospective analysis, all patients with acute/subacute ADB or IMHB treated with SSG between 03/1997 and 08/2024 were evaluated. The primary endpoint was the cumulative incidence of reintervention using a competing risk model over a median follow-up of 6.9 years (range 1.7 months-16.9 years). Secondary endpoints included technical success, aortic remodeling (AR), and false lumen thrombosis (FLT). <i>Results:</i> Of 270 TEVAR-treated patients with ADB or IMHB, 30 (16 ADB, 14 IMHB) underwent SSG. The cumulative incidence of reintervention at 30 days, one year, and three years was 6.7%, 16.7%, and 20%, respectively. Technical success was 100% with no 30-day mortality, stroke, or spinal ischaemia. Limited FLT occurred in 29/30, complete AR in 22/30. Reinterventions (7/30-23.3%) were distal (4) or proximal (3) extensions. Six-year survival was 66.7%. <i>Conclusions:</i> SSG demonstrated perioperative safety and mid-term efficacy beyond the IFU. However, higher reintervention rates - mainly proximal or distal extensions - may be expected, reflecting a trade-off for enhanced spinal cord protection in distal thoracic lesions when applied in carefully selected patients.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147366783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes and costs of AngioJet™ versus lysis-first strategy in acute limb ischemia treatment.","authors":"Nikolaos Papatheodorou, Konstantinos Stavroulakis, Jan Stana, Nikolaos Tsilimparis, Nikolaos Konstantinou","doi":"10.1024/0301-1526/a001273","DOIUrl":"https://doi.org/10.1024/0301-1526/a001273","url":null,"abstract":"<p><p><b></b> <i>Background:</i> This study compared outcomes of a pharmacomechanical thrombectomy (PMT)-first strategy using the AngioJet™ system versus catheter-directed thrombolysis (CDT) in the treatment of acute limb ischemia (ALI). <i>Patients and methods:</i> We retrospectively analysed 100 patients with ALI (Rutherford I-IIb) treated between January 2016 and September 2024. Patients received either primary PMT with AngioJet™ (n = 57) or primary CDT (n = 43). The primary endpoint was amputation-free survival (AFS). Secondary endpoints included technical success, major amputation, mortality, reintervention, and in-hospital cost. Cox regression was used for time-to-event data; cost analysis employed a generalised linear model. <i>Results:</i> Technical success was higher with AngioJet™ (96.5% vs. 65.1%, p < .001). Median thrombolysis duration (1 h vs. 24 h, p < .001), hospital stay (6 vs. 11 days, p = .002), and ICU stay (1 vs. 2 days, p < .001) were significantly reduced. Median inpatient costs were lower in the AngioJet™ group (€9,298 vs. €13,790; exp(B) 1.308, 95% CI 1.07-1.6, p = .009). No significant differences were observed in 30-day mortality, major amputation, bleeding, or acute kidney injury. At 12-months AFS was similar (57.9% vs. 51.2%, p = .55). While major amputation was less frequent after AngioJet™ (5.4% vs. 18.6%, p = .05), this was not significant in multivariate analysis. CDT was independently associated with higher reintervention rates (HR 2.57, p = .03). <i>Conclusions:</i> In this cohort, a primary AngioJet™ strategy was associated with advantages in technical outcomes, hospitalisation, costs, and reinterventions, while amputation-free survival remained comparable to primary CDT. These findings support its use as an effective endovascular option in selected ALI patients.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147366697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delphi consensus on diagnostic and therapeutic pathways for pelvic venous disorders - A multidisciplinary algorithm.","authors":"Domenico Baccellieri, Antonio Basile, Alessandro Arena, Annarita Dapoto, Alessandra De Cicco Nardone, Attilio Di Spiezio Sardo, Lorenza Driul, Roberto Iezzi, Liliana Mereu, Francesco Modestino, Vincenzo Ardita, Pier Luigi Antignani","doi":"10.1024/0301-1526/a001267","DOIUrl":"https://doi.org/10.1024/0301-1526/a001267","url":null,"abstract":"<p><p><b></b> <i>Background:</i> Pelvic venous disorders (PeVD) are associated with chronic pelvic pain and varicose veins due to venous insufficiency and pooling in the pelvis. Despite increasing interest, there is a lack of widely accepted diagnostic algorithms and validated criteria, which complicates diagnosis and management. This study aimed to develop and validate a diagnostic and therapeutic algorithm for PeVD using expert consensus. <i>Materials and methods:</i> An independent Advisory Board (AB) of 11 Italian specialists (gynaecologist, radiologists, vascular surgeons, and angiologists) was convened. A literature review informed the development of a draft algorithm. Three Delphi survey rounds were conducted, with online and in-person discussions, and a consensus threshold set at ≥70%. <i>Results:</i> All 11 AB members completed the first two survey rounds, and eight completed the third. The median number of diagnosed and treated PeVD cases per expert was 20 and 12 per year, respectively. The group agreed on classifying PeVD into Pelvic Congestion Syndrome (PCS) and compressive/obstructive syndromes. Endovascular therapy was recognised as standard of care: pelvic embolisation for PCS, stenting for obstructive lesions, and combined approaches when both are present. Clinical success was defined as subjective symptom improvement assessed 3-6 months post-procedure. Treatment failure warranted re-evaluation and possible reintervention. Surgical treatment was considered only when conservative and endovascular options failed (37.5% agree, 50% neutral). <i>Conclusions:</i> This Delphi-based consensus produced a validated, multidisciplinary algorithm for the diagnosis and treatment of PeVD. It highlights the need for standardised clinical pathways, but further validation by a broader expert community is warranted.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147356692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with all-cause mortality in endovascularly treated patients with diabetes mellitus and lower extremity peripheral arterial disease.","authors":"Mária Rašiová, Veronika Pavlíková, Marek Hudák, Viktor Kožár, Barbara Čeryová, Laura Tomečková, Adriana Rašiová","doi":"10.1024/0301-1526/a001277","DOIUrl":"https://doi.org/10.1024/0301-1526/a001277","url":null,"abstract":"<p><p><b></b> <i>Background:</i> This study aimed to examine 5-year all-cause mortality in endovascularly treated patients with peripheral arterial disease of the lower extremities with and without diabetes mellitus (DM), and to identify factors associated with mortality in the DM subgroup. <i>Patients and methods:</i> Patients treated between January 2016 and December 2018 were analysed. Multivariable models were adjusted for age, sex, smoking, chronic limb-threatening ischaemia (CLTI), malignancy, dyslipoproteinaemia, heart failure, fibrinogen, and estimated glomerular filtration rate (eGFR). <i>Results:</i> A total of 676 patients were included; 59.6% had DM. Patients with DM had higher mortality compared to those without DM (56.8% vs. 37.0%, p < .001). DM was associated with higher mortality in univariable analysis (hazard ratio (HR) 1.73; p < .001), but not in multivariable analysis (HR 1.19; p = .329). Among patients with DM, higher mortality was associated with CLTI (HR 1.62; p = .022), and treatment of two or three anatomical regions (HR 1.36; p = .033). Higher fibrinogen (HR 1.17 per 1 g/L; p < .001) and lower eGFR (HR 0.98 per 1 ml/min/1.73 m²; p < .001) were associated with increased mortality. Mortality was lower in patients who underwent ipsilateral reintervention (HR 0.61; p = .005), amputation (HR 0.65; p = .011), or contralateral intervention (HR 0.58; p = .004). <i>Conclusions:</i> Mortality did not differ between patients with and without DM after multivariable adjustment. In patients with DM, CLTI, multiregional treatment, higher fibrinogen, and lower eGFR were associated with increased mortality; ipsilateral reintervention, amputation, and contralateral intervention were linked to lower mortality.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and cost analysis of plug-based versus suture-based vascular closure devices for percutaneous large bore aortic procedures.","authors":"Kareem El Sherbiny, Natasha Hasemaki, Theodosios Bisdas, Yassine Haddad, Sallameh Al-Jamal, Konstantinos Stavroulakis","doi":"10.1024/0301-1526/a001278","DOIUrl":"https://doi.org/10.1024/0301-1526/a001278","url":null,"abstract":"<p><p><b></b> <i>Background:</i> To compare the clinical outcomes and the costs of the plug-based- versus suture-based vascular closure device following large-bore percutaneous aortic procedures. <i>Materials and methods:</i> This single-centre retrospective analysis included 68 consecutive patients undergoing endovascular aortic procedures between January 2024 and May 2025. Femoral artery closure was achieved using either the MANTA (Teleflex, Wayne, Pennsylvania) or Perclose ProStyle (Abbott Vascular, Abbott Park, Il) vascular closure device. Procedural details, anatomical parameters, and access-site outcomes were analysed. The primary endpoint was technical success. Secondary endpoints included bleeding, vessel occlusion, pseudoaneurysm, access-site thrombosis, surgical conversion, and device-related cost per access site. <i>Results:</i> Sixty-eight patients with 111 femoral access sites (71 MANTA, 40 Perclose ProStyle) were included. No differences were observed between groups regarding aortic pathology, access vessel diameter, or calcification severity. Technical success was high in both groups (97.5% Perclose ProStyle vs. 93.0% MANTA; p = .312). Access-site complications occurred more frequently in the MANTA group, including all pseudoaneurysms (2.8%) and most surgical conversions (7.0% vs. 2.5%), although differences were not statistically significant. No access-site thrombosis was observed. Mean device-related cost per access site was significantly higher for MANTA than for Perclose ProStyle (€466 vs. €290; p = .001). <i>Conclusions:</i> Both MANTA and Perclose ProStyle devices achieved high rates of successful large-bore femoral closure. However, the suture-based ProGlide system was associated with lower cost and fewer access-site complications. Given the retrospective design and operator-driven device selection, these findings should be interpreted with caution.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the societies.","authors":"","doi":"10.1024/0301-1526/a001270","DOIUrl":"https://doi.org/10.1024/0301-1526/a001270","url":null,"abstract":"","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":"55 2","pages":"162-163"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147327133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"iCover as bridging stent graft in complex endovascular aortic repair.","authors":"Oana Bartos, Judith Reidt, Oleg Krassilnikov, Dagmar Bachhuber, Matthias Trenner","doi":"10.1024/0301-1526/a001239","DOIUrl":"10.1024/0301-1526/a001239","url":null,"abstract":"<p><p><b></b> <i>Background:</i> Bridging Stent Grafts (BSG) are an essential element of fenestrated and branched endovascular aortic repair (FEVAR and BEVAR respectively). Until CE marking of a dedicated stent in late 2024, a variety of BSG were used. The aim of this study was to evaluate the outcomes of the iCover stent graft in this application. <i>Patients and methods:</i> We retrospectively analysed 22 consecutive patients treated at our institution with FEVAR and BEVAR between 05/2023 and 09/2024. The primary endpoint is a composite of target vessel (TV) technical success and freedom from target vessel instability (TVI) in the early and short-/mid-term phase. Secondary endpoints consisted of early, short- and mid-term clinical outcomes. <i>Results:</i> Ninety-seven iCover stent grafts were used to bridge 90 target vessels: 23 for the coeliac arteries (CA), 23 for the superior mesenteric artery (SMA) and 50 for the renal arteries (RA); one iCover stent could not be implanted. The underlying aortic pathology was juxtarenal and pararenal aneurysm (12/22; 54,5%), penetrating aortic ulcer (PAU) (2/22; 9%), type Ia endoleak following infrarenal EVAR (3/22; 13,6%), chronic type B aortic dissection with aneurysmal degeneration (1/22; 4,5%), Safi type IV (3/22; 13.6%) and Safi type V (1/22; 4.5%) thoraco-abdominal aortic aneurysm (TAAA). The mean aneurysm diameter was 60,5 mm (+/- 10,6 mm). Four (18,2%) patients underwent urgent procedures. The median follow-up was 291,5 days (IQR 63-425,2). 3 patients (13,6%) died from non-aneurysm-related causes. Assisted primary TV technical success was 98,88% (89/90). One non-iCover related loss of TV was excluded from mid-term analysis. The TV patency was 98,88% (89/90) in the early phase and 98,87% (88/89) at mid-term follow-up. Cumulative freedom from TVI was 92,13% (82/89). <i>Conclusions:</i> The iCover is effective and safe to use as a BSG in fenestrated endovascular aortic repair. Our results align with the available literature, but further studies are needed to validate iCover as BGS, especially in BEVAR.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"135-143"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}